Clinical trial Recruiting at 1 site Observational Ages 18 to 65

DT-TUG Protocols: Checking if Three Ways to Do the Dual-Task Timed Up and Go Are Reliable

Official title: Comparison of the Reliability and Convergent Validity of Three Dual-Task Timed Up and Go Protocols in People With Multiple Sclerosis

Run by Afyonkarahisar Health Sciences University · NCT07788859 · Data updated 2026-11-12

This study tests three methods of the dual-task Timed Up and Go test to see which is most reliable for adults with multiple sclerosis.

Quick facts

Study typeObservational
Ages18 Years to 65 Years
SexAll
Enrollment40 (estimated)
SponsorAfyonkarahisar Health Sciences University
Academic / other
Locations1 site (Gaziantep)
StatusRecruiting
StartedMarch 16, 2026
Main results expectedSeptember 14, 2026
Study endsSeptember 14, 2026
Registry record updatedAugust 27, 2026
Trial IDNCT07788859 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–65 with a confirmed MS diagnosis (McDonald criteria 2017), EDSS 0–5.5, able to walk without aids.

Probably not a fit

Individuals with higher disability (EDSS >5.5), recent relapse, or other neurological or sensory impairments may not benefit from these protocols.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares three dual-task Timed Up and Go protocols to determine their validity and reliability in people with multiple sclerosis. Researchers will assess convergent validity, intra-rater and inter-rater reliability, and calculate measurement error metrics such as SEM and MDC. Bland-Altman plots will be used to visualize agreement between raters. The study uses subtasks of counting backward in threes, verbal fluency, and ball-carrying on a tray to form the dual-task DTUG tests. Participants are adults with MS, 18–65, with EDSS 0–5.5, who do not use walking aids and meet other eligibility criteria, and the lead sponsor is Afyonkarahisar Health Sciences University in collaboration with SANKO University in Gaziantep, Turkey.

Why it matters

Potential benefit: If successful, clinicians could choose a validated and reliable DTUG protocol to better assess dual-task walking in MS and potentially guide fall-risk management.

How similar studies have gone: Previous research shows that dual-task assessments can be informative, but this study directly compares three DTUG protocols for reliability and validity in MS.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Having been diagnosed with MS according to the McDonald criteria revised in 2017,
* Being between the ages of 18 and 65,
* Having an Expanded Disability Status Scale (EDSS) score between 0 and 5.5,
* Not requiring any assistive walking devices.

Exclusion Criteria:

* Pregnancy;
* Having experienced a relapse within the past three months;
* The presence of another neurological condition in addition to MS;
* The presence of a different disorder that could potentially affect gait parameters;
* The presence of visual, auditory, perceptual, or cognitive impairments severe enough to interfere with the test administration

Where it's running

  • SANKO University
    Gaziantep, Turkey (Türkiye)
    Recruiting

Study contacts

  • Principal investigator: Emel TAŞVURAN HORATA, PhD — Afyonkarahisar Health Sciences University
  • Study coordinator: EMEL TAŞVURAN HORATA, PhD
  • Email: ethorata@gmail.com
  • Phone: 05547759663

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.